Drug Trial Radar · NCT06402838
A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
256
Actual
Start
May 2, 2024
Primary completion
Nov 19, 2026
Study completion Nov 19, 2026
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- May 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is recruiting people who either are at risk of AD - have build-up of beta-amyloid, but have no clinical symptoms, or with a diagnosis of mild cognitive impairment. People can take part if they have a certain level of plaques (beta-amyloid) in the brain, shown by a positron emission tomography (PET) scan, a medical imaging technique in which tracers are injected to visualize specific pathological processes in the brain. People who take part in this clinical trial (participants) will be given RO7269162 OR placebo for up to about 1 and a half years. The clinical trial team will see them every 3 weeks in the first 3 months and then every 6 weeks until the end of the trial. These hospital visits will include checks to see how the participant responds to the treatment and any side effects they may have. The total time of participation in the clinical trial will be 90 weeks.
Conditions
- Alzheimer's Disease
Interventions
RO7269162Drug
Participants will receive daily doses (one of three dose levels) of RO7269162 for up to 72 weeks.
PlaceboDrug
Participants will receive daily doses of placebo for up to 72 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs)Time frame: up to week 72
- Change from baseline in brain amyloid load, as measured by amyloid positron emission tomography ( PET) scanTime frame: Baseline to Week 72
Locations
45 sites in 9 countries. Site status is shown where the registry gives one.
Centro de Investigación Clínica UC-CICUC
Santiago, Chile
Hospital Clinico Univ de Chile
Santiago, Chile
Aarhus Universitetshospital Skejby
Aarhus N, Denmark
Rigshospitalet, Hukommelsesklinikken
Koebenhavn Oe, Denmark
Groupement Hospitalier Est - Hôpital Neurologique
Bron, France
Hopital B Roger Salengro
Lille, France
Hôpital de la Timone
Marseille, France
Hôpital Lariboisière
Paris, France
CHU de Rouen Hopital
Rouen, France
Hop Guillaume Et Rene Laennec
Saint-Herblain, France
Hôpital Robertsau
Strasbourg, France
Gerontopole
Toulouse, France
Ambulates Gesundheitszentrum der Charité GmbH
Berlin, Germany
TUM Klinikum rechts der Isar;Ambulanz für neurokognitive Erkrankungen
München, Germany
Ospedale Cardinale Panico
Tricase (LE), Apulia, Italy
Umberto I Policlinico di Roma-Università di Roma La Sapienza
Rome, Lazio, Italy
IRCCS Ospedale San Raffaele
Milan, Lombardy, Italy
Fondazione Istituto Neurologico Mondino IRCCS
Pavia, Lombardy, Italy
ProNeuro Centrum Medyczne
?ory, Poland
Podlaskie Centrum Psychogeriatrii
Bia?ystok, Poland
NZOZ Vitamed
Bydgoszcz, Poland
NEURO-CARE Sp. z o.o. Sp. Komandytowa
Katowice, Poland
Szpital Uniwersytecki w Krakowie
Krakow, Poland
Senior Sp. Z O.O. Poradnia Psychogeriatryczna
Sopot, Poland
EUROMEDIS Sp z o o
Szczecin, Poland
ETG Neuroscience Sp. z o.o.
Warsaw, Poland
NZOZ WCA
Wroc?aw, Poland
Gachon University Gil Medical Center
Incheon, South Korea
Fundacio ACE
Barcelona, Spain
Hospital Universitario Reina Sofia
Córdoba, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Victoria Eugenia
Seville, Spain
Hospital Virgen del Rocío
Seville, Spain
Hospital Universitario Dr. Peset
Valencia, Spain
Hospital Universitario la Fe
Valencia, Spain
Hospital General De Catalunya
Sant Cugat del Vallès, Barcelona, Spain
Policlínica Guipuzcoa
Donostia / San Sebastian, Guipuzcoa, Spain
Hospital Quiron de Madrid
Pozuelo de Alarcón, Madrid, Spain
Complejo Asistencial Universitario de Salamanca
Salamaca, Salamanca, Spain
Surrey and Borders NHS Foundation Trust
Chertsey, United Kingdom
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.